Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. The treatment o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC veterinary research 2015-08, Vol.11 (1), p.210-210, Article 210
Hauptverfasser: Olivry, Thierry, DeBoer, Douglas J, Favrot, Claude, Jackson, Hilary A, Mueller, Ralf S, Nuttall, Tim, Prélaud, Pascal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 210
container_issue 1
container_start_page 210
container_title BMC veterinary research
container_volume 11
creator Olivry, Thierry
DeBoer, Douglas J
Favrot, Claude
Jackson, Hilary A
Mueller, Ralf S
Nuttall, Tim
Prélaud, Pascal
description In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD. This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.
doi_str_mv 10.1186/s12917-015-0514-6
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4537558</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541462437</galeid><sourcerecordid>A541462437</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-1b61e4f6e1ed4855bda720cca004a369feca3ad44d9574609d76992e8d3a67eb3</originalsourceid><addsrcrecordid>eNptkk1rFTEUhoMotlZ_gBsJuKmLqclMPmZcCMOtH4WCm7oOucmZ28hMck0ygr_Av-253FpakCzy9bzvyUsOIa85u-C8V-8LbweuG8ZlwyQXjXpCTrkWqlFc9E8frE_Ii1J-MCbEoNVzctKqViuUnJI_NxlsXSBWmibqbAwRqK1pHxz1kBdbQw3lA22xCF333lbwdLcGDzOShU45LbTeAr2KFXJEPEU7001allArAE2RjvMMeYeGl6GALajCUmMMi50LPb_ajJfju5fk2YRbeHU3n5Hvnz_dbL4219--IHHdONm1teFbxUFMCjh40Uu59Va3zDmL2Wynhgmc7awXwg8Sw7PBazUMLfS-s0rDtjsjH4---3W7gHcYPNvZ7DO-Jv82yQbz-CaGW7NLv4yQnZayR4PzO4Ocfq5QqllCcTDPNkJai-GaScY44x2ib4_ozs5gQpwSOroDbkYpuFCt6DRSF_-hcHhYgksRpoDnjwT8KHA5lZJhun89Z-bQF-bYFwa_zBz6wijUvHkY-17xrxG6v0k2s54</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1705001013</pqid></control><display><type>article</type><title>Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Olivry, Thierry ; DeBoer, Douglas J ; Favrot, Claude ; Jackson, Hilary A ; Mueller, Ralf S ; Nuttall, Tim ; Prélaud, Pascal</creator><creatorcontrib>Olivry, Thierry ; DeBoer, Douglas J ; Favrot, Claude ; Jackson, Hilary A ; Mueller, Ralf S ; Nuttall, Tim ; Prélaud, Pascal ; International Committee on Allergic Diseases of Animals ; for the International Committee on Allergic Diseases of Animals</creatorcontrib><description>In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD. This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.</description><identifier>ISSN: 1746-6148</identifier><identifier>EISSN: 1746-6148</identifier><identifier>DOI: 10.1186/s12917-015-0514-6</identifier><identifier>PMID: 26276051</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acute Disease ; Administration, Oral ; Administration, Topical ; Advertising executives ; Animals ; Anti-Infective Agents - therapeutic use ; Anti-Inflammatory Agents - therapeutic use ; Atopic dermatitis ; Baths - veterinary ; Care and treatment ; Chronic Disease ; Correspondence ; Dermatitis, Atopic - therapy ; Dermatitis, Atopic - veterinary ; Dermatologic Agents - therapeutic use ; Dog Diseases - drug therapy ; Dogs ; Drug therapy ; Drug Therapy, Combination - veterinary ; Evidence-based medicine ; Glucocorticoids - therapeutic use ; Interferon ; International Cooperation ; Pharmaceutical industry ; Practice Guidelines as Topic ; Pruritus ; Skin</subject><ispartof>BMC veterinary research, 2015-08, Vol.11 (1), p.210-210, Article 210</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Olivry et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-1b61e4f6e1ed4855bda720cca004a369feca3ad44d9574609d76992e8d3a67eb3</citedby><cites>FETCH-LOGICAL-c532t-1b61e4f6e1ed4855bda720cca004a369feca3ad44d9574609d76992e8d3a67eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537558/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537558/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26276051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olivry, Thierry</creatorcontrib><creatorcontrib>DeBoer, Douglas J</creatorcontrib><creatorcontrib>Favrot, Claude</creatorcontrib><creatorcontrib>Jackson, Hilary A</creatorcontrib><creatorcontrib>Mueller, Ralf S</creatorcontrib><creatorcontrib>Nuttall, Tim</creatorcontrib><creatorcontrib>Prélaud, Pascal</creatorcontrib><creatorcontrib>International Committee on Allergic Diseases of Animals</creatorcontrib><creatorcontrib>for the International Committee on Allergic Diseases of Animals</creatorcontrib><title>Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)</title><title>BMC veterinary research</title><addtitle>BMC Vet Res</addtitle><description>In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD. This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.</description><subject>Acute Disease</subject><subject>Administration, Oral</subject><subject>Administration, Topical</subject><subject>Advertising executives</subject><subject>Animals</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Atopic dermatitis</subject><subject>Baths - veterinary</subject><subject>Care and treatment</subject><subject>Chronic Disease</subject><subject>Correspondence</subject><subject>Dermatitis, Atopic - therapy</subject><subject>Dermatitis, Atopic - veterinary</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination - veterinary</subject><subject>Evidence-based medicine</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Interferon</subject><subject>International Cooperation</subject><subject>Pharmaceutical industry</subject><subject>Practice Guidelines as Topic</subject><subject>Pruritus</subject><subject>Skin</subject><issn>1746-6148</issn><issn>1746-6148</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkk1rFTEUhoMotlZ_gBsJuKmLqclMPmZcCMOtH4WCm7oOucmZ28hMck0ygr_Av-253FpakCzy9bzvyUsOIa85u-C8V-8LbweuG8ZlwyQXjXpCTrkWqlFc9E8frE_Ii1J-MCbEoNVzctKqViuUnJI_NxlsXSBWmibqbAwRqK1pHxz1kBdbQw3lA22xCF333lbwdLcGDzOShU45LbTeAr2KFXJEPEU7001allArAE2RjvMMeYeGl6GALajCUmMMi50LPb_ajJfju5fk2YRbeHU3n5Hvnz_dbL4219--IHHdONm1teFbxUFMCjh40Uu59Va3zDmL2Wynhgmc7awXwg8Sw7PBazUMLfS-s0rDtjsjH4---3W7gHcYPNvZ7DO-Jv82yQbz-CaGW7NLv4yQnZayR4PzO4Ocfq5QqllCcTDPNkJai-GaScY44x2ib4_ozs5gQpwSOroDbkYpuFCt6DRSF_-hcHhYgksRpoDnjwT8KHA5lZJhun89Z-bQF-bYFwa_zBz6wijUvHkY-17xrxG6v0k2s54</recordid><startdate>20150816</startdate><enddate>20150816</enddate><creator>Olivry, Thierry</creator><creator>DeBoer, Douglas J</creator><creator>Favrot, Claude</creator><creator>Jackson, Hilary A</creator><creator>Mueller, Ralf S</creator><creator>Nuttall, Tim</creator><creator>Prélaud, Pascal</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150816</creationdate><title>Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)</title><author>Olivry, Thierry ; DeBoer, Douglas J ; Favrot, Claude ; Jackson, Hilary A ; Mueller, Ralf S ; Nuttall, Tim ; Prélaud, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-1b61e4f6e1ed4855bda720cca004a369feca3ad44d9574609d76992e8d3a67eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acute Disease</topic><topic>Administration, Oral</topic><topic>Administration, Topical</topic><topic>Advertising executives</topic><topic>Animals</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Atopic dermatitis</topic><topic>Baths - veterinary</topic><topic>Care and treatment</topic><topic>Chronic Disease</topic><topic>Correspondence</topic><topic>Dermatitis, Atopic - therapy</topic><topic>Dermatitis, Atopic - veterinary</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination - veterinary</topic><topic>Evidence-based medicine</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Interferon</topic><topic>International Cooperation</topic><topic>Pharmaceutical industry</topic><topic>Practice Guidelines as Topic</topic><topic>Pruritus</topic><topic>Skin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olivry, Thierry</creatorcontrib><creatorcontrib>DeBoer, Douglas J</creatorcontrib><creatorcontrib>Favrot, Claude</creatorcontrib><creatorcontrib>Jackson, Hilary A</creatorcontrib><creatorcontrib>Mueller, Ralf S</creatorcontrib><creatorcontrib>Nuttall, Tim</creatorcontrib><creatorcontrib>Prélaud, Pascal</creatorcontrib><creatorcontrib>International Committee on Allergic Diseases of Animals</creatorcontrib><creatorcontrib>for the International Committee on Allergic Diseases of Animals</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC veterinary research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olivry, Thierry</au><au>DeBoer, Douglas J</au><au>Favrot, Claude</au><au>Jackson, Hilary A</au><au>Mueller, Ralf S</au><au>Nuttall, Tim</au><au>Prélaud, Pascal</au><aucorp>International Committee on Allergic Diseases of Animals</aucorp><aucorp>for the International Committee on Allergic Diseases of Animals</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)</atitle><jtitle>BMC veterinary research</jtitle><addtitle>BMC Vet Res</addtitle><date>2015-08-16</date><risdate>2015</risdate><volume>11</volume><issue>1</issue><spage>210</spage><epage>210</epage><pages>210-210</pages><artnum>210</artnum><issn>1746-6148</issn><eissn>1746-6148</eissn><abstract>In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD. This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26276051</pmid><doi>10.1186/s12917-015-0514-6</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1746-6148
ispartof BMC veterinary research, 2015-08, Vol.11 (1), p.210-210, Article 210
issn 1746-6148
1746-6148
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4537558
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerNature Journals; PubMed Central Open Access; PubMed Central; Springer Nature OA/Free Journals
subjects Acute Disease
Administration, Oral
Administration, Topical
Advertising executives
Animals
Anti-Infective Agents - therapeutic use
Anti-Inflammatory Agents - therapeutic use
Atopic dermatitis
Baths - veterinary
Care and treatment
Chronic Disease
Correspondence
Dermatitis, Atopic - therapy
Dermatitis, Atopic - veterinary
Dermatologic Agents - therapeutic use
Dog Diseases - drug therapy
Dogs
Drug therapy
Drug Therapy, Combination - veterinary
Evidence-based medicine
Glucocorticoids - therapeutic use
Interferon
International Cooperation
Pharmaceutical industry
Practice Guidelines as Topic
Pruritus
Skin
title Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T11%3A31%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20canine%20atopic%20dermatitis:%202015%20updated%20guidelines%20from%20the%20International%20Committee%20on%20Allergic%20Diseases%20of%20Animals%20(ICADA)&rft.jtitle=BMC%20veterinary%20research&rft.au=Olivry,%20Thierry&rft.aucorp=International%20Committee%20on%20Allergic%20Diseases%20of%20Animals&rft.date=2015-08-16&rft.volume=11&rft.issue=1&rft.spage=210&rft.epage=210&rft.pages=210-210&rft.artnum=210&rft.issn=1746-6148&rft.eissn=1746-6148&rft_id=info:doi/10.1186/s12917-015-0514-6&rft_dat=%3Cgale_pubme%3EA541462437%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1705001013&rft_id=info:pmid/26276051&rft_galeid=A541462437&rfr_iscdi=true